ViroGates has developed a novel method to monitor patient disease progression. The technique involves measurement of a protein found in human blood - known as V-suPAR - whose elevated levels are indicative of poor patient prognosis or disease outcome. Measuring V-suPAR serves to evaluate a patient's health status and is used in within specific disease indications, including Sepsis, Tuberculosis and HIV. This technique is commercially realised in suPARnostic - ViroGates first product.